靶向肿瘤相关内皮细胞使用[68Ga]Ga-PSMA-617对肝细胞癌进行PET显像
本研究制备[68Ga]Ga-PSMA-617,在HepG2和HuH-7细胞及皮下、原位和患者来源异种移植瘤(PDX)模型中进行小动物PET与生物分布研究,结果显示肿瘤摄取高于阻断组,PET图像清晰显示肿瘤位置,组织染色证实显像可能通过靶向肿瘤相关内皮细胞介导。
要点
- HepG2和HuH-7细胞PSMA表达水平低,细胞摄取与阻断研究证实探针结合为非特异性。
- 皮下移植瘤0.5小时肿瘤摄取HepG2为0.76±0.12%ID/g、HuH-7为0.78±0.08%ID/g,显著高于对应阻断组。
- 原位及PDX模型PET显示肿瘤摄取清晰、肿瘤/背景对比突出,染色证实肿瘤相关血管内皮表达PSMA。
核心结论
- 在不同类型肝细胞癌异种移植模型中,[68Ga]Ga-PSMA-617 PET显示肿瘤内高摄取,证实该显像可能通过靶向肿瘤相关内皮细胞而成为肝细胞癌有前景的显像方法。
研究设计与样本
- 研究制备[68Ga]Ga-PSMA-617,评估HepG2和HuH-7细胞PSMA表达及细胞摄取,并构建HepG2和HuH-7皮下移植瘤、HepG2原位移植瘤及四组PDX模型。
- 采用小动物PET和生物分布研究评估[68Ga]Ga-PSMA-617在不同类型肝细胞癌异种移植模型中的临床前药代动力学和显像性能。
主要发现
- HepG2和HuH-7细胞PSMA表达水平低,细胞摄取和阻断研究证实PSMA靶向探针与HepG2和HuH-7细胞结合为非特异性。
- 皮下移植瘤0.5小时肿瘤摄取HepG2为0.76±0.12%ID/g、HuH-7为0.78±0.08%ID/g,分别显著高于对应阻断组的0.23±0.04%ID/g和0.20±0.04%ID/g。
- 原位移植瘤模型中,PET图像基于[68Ga]Ga-PSMA-617在肿瘤组织较正常肝组织的优先聚集清晰显示肿瘤位置,提示可用于检测深部组织原发肝细胞癌病灶。
- 四组肝细胞癌PDX模型中,[68Ga]Ga-PSMA-617 PET显示清晰肿瘤摄取和突出肿瘤/背景对比,进一步展示其对PSMA阳性肝细胞癌病灶临床显像的潜力。
- 皮下、原位和PDX肿瘤组织切片CD31和PSMA特异性抗体染色显示肿瘤相关血管及内皮细胞PSMA表达,证实[68Ga]Ga-PSMA-617显像可能由靶向肿瘤相关内皮细胞介导。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hepatocellular carcinoma (HCC) is a malignant tumor associated with high morbidity and mortality rates. In many non-prostate solid tumors such as HCC, prostate-specific membrane antigens (PSMA) are overexpressed in tumor-associated endothelial cells. Therefore, the aim of this study was to evaluate the performance of [68Ga]Ga-PSMA-617 PET imaging on HCC with different animal models, including cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), and to explore its mechanisms of function. METHODS: [68Ga]Ga-PSMA-617 was prepared. The expression level of PSMA in two human hepatocellular cancer cells (HepG2 and HuH-7) was evaluated, and the cellular uptakes of [68Ga]Ga-PSMA-617 were assayed. HepG2 and HuH-7 subcutaneous xenograft models, HepG2 orthotopic xenograft models, and four different groups of PDX models were prepared. Preclinical pharmacokinetics and performance of [68Ga]Ga-PSMA-617 were evaluated in different types of HCC xenografts models using small animal PET and biodistribution studies. RESULTS: Low PSMA expression level of HepG2 and HuH-7 cells was observed, and the cellular uptake and blocking study confirmed the non-specificity of the PSMA-targeted probe binding to HepG2 and HuH-7 cells. In the subcutaneous xenograft models, the tumor uptakes at 0.5 h were 0.76 ± 0.12%ID/g (HepG2 tumors) and 0.78 ± 0.08%ID/g (HuH-7 tumors), respectively, which were significantly higher than those of the blocking groups (0.23 ± 0.04%ID/g and 0.20 ± 0.04%ID/g, respectively). In the orthotopic xenograft models, PET images clearly displayed the tumor locations based on the preferential accumulation of [68Ga]Ga-PSMA-617 in tumor tissue versus normal liver tissue, suggesting the possibility of using [68Ga]Ga-PSMA-617 PET imaging to detect primary HCC lesions in deep tissue. In the four different groups of HCC PDX models, PET imaging with [68Ga]Ga-PSMA-617 provided clear tumor uptakes with prominent tumor-to-background contrast, further demonstrating its potential for the clinical imaging of PSMA-positive HCC lesions. The staining of tumor tissue sections with CD31- and PSMA-specific antibodies visualized the tumor-associated blood vessels and PSMA expression on endothelial cells in subcutaneous, orthotopic tissues, and PDX tissues, confirming the imaging with [68Ga]Ga-PSMA-617 might be mediated by targeting tumor associated endothelium. CONCLUSION: In this study, in vivo PET on different types of HCC xenograft models illustrated high uptake within tumors, which confirmed that [68Ga]Ga-PSMA-617 PET may be a promising imaging modality for HCC by targeting tumor associated endothelium.
引用
- Lu Q, Long Y, Fan K, et al. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617. Eur J Nucl Med Mol Imaging. 2022. PMID: 35763056. doi:10.1007/s00259-022-05884-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。